Key result
This study protocol describes a randomized controlled trial to evaluate whether a postoperative cholecalciferol loading dose significantly increases 25-hydroxy-vitamin D levels at 24 weeks in bariatric patients.
Why the study?
Does a cholecalciferol loading dose regimen improve vitamin D levels in bariatric patients undergoing omega-loop gastric bypass surgery?
RCT (n=50)
Double-blind
Stratified randomization
No
Does a cholecalciferol loading dose regimen improve vitamin D levels in bariatric patients undergoing omega-loop gastric bypass surgery?
This study protocol outlines a trial to evaluate the efficacy and safety of a high-dose vitamin D loading regimen compared to standard supplementation in bariatric surgery patients.
BACKGROUND: Beyond its classical role in calcium homoeostasis and bone metabolism, vitamin D deficiency has been found to be associated with several diseases, including diabetes, non-alcoholic fatty liver disease, and even obesity itself. Importantly, there are limited data on therapeutic strategies for vitamin D deficiency in bariatric patients, and the procedure-specific guidelines may not be sufficient. To improve long-term outcomes, nutritional screening and appropriate supplementation to prevent nutrient deficiencies are urgently needed. Therefore, the aim of this study is to examine effects and safety of a forced dosing regimen of vitamin D versus conventional dose supplementation on vitamin D levels and other parameters in bariatric patients. METHODS/DESIGN: The study includes loading plus repeat dosing compared with repeated administration of vitamin D without a loading dose, according to guidelines, in a prospective, double-blind, randomized controlled trial. Up to a triple oral loading dose is given on day 1, then 2 and 4 weeks after surgery (100,000 IU dose each time), followed by an oral maintenance dose (3420 IU/day). The control group (n = 25) will receive placebo, followed by administration of a standard dose (3420 IU/day). We hypothesize that a significant increase in vitamin D levels will occur in patients in the treatment group (n = 25) by 24 weeks after surgery. Further measurements are aimed at evaluating changes in inflammation, bone turnover, insulin resistance, blood pressure, liver, mental health, and gut microbiota of patients undergoing omega-loop gastric bypass surgery. Furthermore, possible associations between concentrations of vitamin D, the involved enzymes, or vitamin D receptor in adipose and/or liver tissues will be determined. DISCUSSION: To our knowledge, this trial is the first of its kind with this type of vitamin D supplementation in bariatric patients. Its major strength is the design and implementation of evaluation of influencing factors such as liver function, bone health, inflammation, insulin resistance, blood pressure, symptoms of depression, or microbiota. This alternative vitamin D dosing regimen has the potential to be a safe, fast, evidence-based treatment of vitamin D deficiency in bariatric patients. Owing to the increasing number of bariatric patients, it is also of interest to elucidate the link between obesity and vitamin D. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT02092376 . Registered on 17 March 2014.
No takes yet. Share an insight, caveat, or question.
Luger et al. (2015) conducted an RCT in Obesity and vitamin D deficiency in bariatric patients (n=50). Cholecalciferol (Vitamin D3) loading dose vs. Placebo loading dose followed by 3420 IU/day maintenance was evaluated on 25-OHD levels 24 weeks after surgery. This study protocol describes a randomized controlled trial to evaluate whether a postoperative cholecalciferol loading dose significantly increases 25-hydroxy-vitamin D levels at 24 weeks in bariatric patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: